Financhill
Back

Monte Rosa Therapeutics Vs. Revance Therapeutics Industry Stock Comparison

Sell
23

GLUE
Monte Rosa Therapeutics

Last Price:
$7.16
Seasonality Move:
0.27%
Sell
5

RVNC
Revance Therapeutics

Last Price:
$3.09
Seasonality Move:
-4.05%
Sell
23
Monte Rosa Therapeutics (GLUE) is a Sell

Is Monte Rosa Therapeutics a Buy, Sell or Hold?

  • The current Monte Rosa Therapeutics [GLUE] share price is $7.17. The Score for GLUE is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.
  • GLUE is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
5
Revance Therapeutics (RVNC) is a Sell

Is Revance Therapeutics a Buy, Sell or Hold?

  • The current Revance Therapeutics [RVNC] share price is $3.09. The Score for RVNC is 5, which is 90% below its historic median score of 50, and infers higher risk than normal.
  • RVNC is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing an extreme reading that indicates risk could be especially high.

GLUE Stock Price Chart

What is Monte Rosa Therapeutics's stock price today?

  • The Monte Rosa Therapeutics share price today is $7.17
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and GLUE is experiencing selling pressure, which indicates risk of future bearish movement.

RVNC Stock Price Chart

What is Revance Therapeutics's stock price today?

  • The Revance Therapeutics share price today is $3.09
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and RVNC is experiencing buying pressure, which is a positive indicator for future bullish movement.

GLUE Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.38 Sell
Relative Strength Index (14 RSI): 43.57 Sell
Chaikin Money Flow: -338857 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (6.89 - 9.35) Sell
Bollinger Bands (100): (5.26 - 8.58) Buy

RVNC Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.25 Sell
Relative Strength Index (14 RSI): 35.47 Sell
Chaikin Money Flow: 1273712 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (2.93 - 3.65) Sell
Bollinger Bands (100): (3.7 - 6.28) Sell

GLUE Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 7.09 Buy
20-day SMA: 7.71 Sell
50-day SMA: 8.23 Sell
200-day SMA: 5.95 Buy
8-day EMA: 7.14 Buy
20-day EMA: 7.55 Sell
50-day EMA: 7.63 Sell
200-day EMA: 6.42 Buy

RVNC Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 3.07 Buy
20-day SMA: 3.15 Sell
50-day SMA: 4.02 Sell
200-day SMA: 4.26 Sell
8-day EMA: 3.08 Buy
20-day EMA: 3.24 Sell
50-day EMA: 3.82 Sell
200-day EMA: 5.37 Sell

Monte Rosa Therapeutics Earnings Growth & GLUE Earnings Dates

  • Analysts estimate an earnings decrease this quarter of $0.06 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.48 per share, and a decrease next year of $0.24 per share.

Revance Therapeutics Earnings Growth & RVNC Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.31 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.63 per share, and an increase next year of $0.60 per share.

Monte Rosa Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Revance Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):